Puma Biotechnology Inc PBYI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PBYI is a good fit for your portfolio.
News
-
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
-
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
-
Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results
-
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Puma Biotechnology to Participate in a Panel Discussion at TD Cowen’s 44th Annual Health Care Conference
-
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
-
Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer
Trading Information
- Previous Close Price
- $4.83
- Day Range
- $4.74–4.81
- 52-Week Range
- $2.15–7.72
- Bid/Ask
- $4.72 / $4.76
- Market Cap
- $228.98 Mil
- Volume/Avg
- 11,968 / 616,735
Key Statistics
- Price/Earnings (Normalized)
- 7.20
- Price/Sales
- 0.97
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 185
- Website
- http://www.pumabiotechnology.com
Comparables
Valuation
|
Metric
|
PBYI
|
EXEL
|
TGTX
|
|---|---|---|---|
Price/Earnings (Normalized) | 7.20 | 25.86 | 17.99 |
Price/Book Value | 4.31 | 3.11 | 13.44 |
Price/Sales | 0.97 | 4.09 | 9.06 |
Price/Cash Flow | 5.12 | 21.56 | 39.74 |
Price/Earnings
PBYI
EXEL
TGTX
Financial Strength
|
Metric
|
PBYI
|
EXEL
|
TGTX
|
|---|---|---|---|
Quick Ratio | 1.45 | 3.13 | 5.00 |
Current Ratio | 1.57 | 3.34 | 5.92 |
Interest Coverage | 2.51 | — | 2.04 |
Quick Ratio
PBYI
EXEL
TGTX
Profitability
|
Metric
|
PBYI
|
EXEL
|
TGTX
|
|---|---|---|---|
Return on Assets (Normalized) | 15.12% | 9.47% | 19.44% |
Return on Equity (Normalized) | 93.62% | 11.88% | 54.76% |
Return on Invested Capital (Normalized) | 28.62% | 8.36% | 35.76% |
Return on Assets
PBYI
EXEL
TGTX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ywtggdny | Cfkzp | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pvjflchs | Flvsbrn | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Nyscczqf | Nsvpn | $99.5 Bil | |
MRNA
| Moderna Inc | Vpkgvnlx | Mjfy | $38.8 Bil | |
ARGX
| argenx SE ADR | Mxzxjshwx | Yrgxy | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Ggwrcyky | Zkv | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Bzgptymw | Rhxhk | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Bjwlpcvm | Kznhqnc | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ppjzkksc | Nbcth | $12.5 Bil | |
INCY
| Incyte Corp | Gpwfzjggv | Hcyst | $11.6 Bil |